Neuren announced today that it has completed the Phase 2 clinical trial of trofinetide in pediatric Rett syndrome. Top-line results from the trial are anticipated to be received in late March 2017. Neuren is also making plans for a pivotal Phase 3 trial in the future. Two non-clinical chronic toxicity studies of trofinetide will be performed to supplement data for the Phase 3 study design; these studies are scheduled to end in the first half of 2018.
Rettsyndrome.org thanks all those involved with the study trial, the clinicians and teams at the 12 sites and at Neuren, and all the pioneering girls and their families who made great efforts to participate. We especially give thanks to those continue to donate to our mission to support this trial.
NEU Price at posting:
7.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)